{
  "id": "c14b43ab53b7b14b",
  "title": "IGC Pharma Reports 65 % Patient Enrollment Milestone in Phase 2 CALMA Alzheimer Agitation Trial",
  "description": "20251209T181500Z",
  "content": "",
  "source": "californiatelegraph.com",
  "source_url": "http://www.californiatelegraph.com/news/278745498/igc-pharma-reports-65-patient-enrollment-milestone-in-phase-2-calma-alzheimer-agitation-trial",
  "published_at": "20251209T181500Z",
  "fetched_at": "2025-12-10T00:22:54.894572+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "llm"
  ],
  "location": "United States",
  "raw_data": {
    "url": "http://www.californiatelegraph.com/news/278745498/igc-pharma-reports-65-patient-enrollment-milestone-in-phase-2-calma-alzheimer-agitation-trial",
    "url_mobile": "",
    "title": "IGC Pharma Reports 65 % Patient Enrollment Milestone in Phase 2 CALMA Alzheimer Agitation Trial",
    "seendate": "20251209T181500Z",
    "socialimage": "",
    "domain": "californiatelegraph.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}